Competitive antagonists shift the dose-effect curve for an agonist (e.g. the endogenous neurotransmitter) to the right, but this effect can eventually be overcome by enough agonist concentration.

file_download Download in HQ

Related content

description Article
Genetics in Parkinson’s disease – coming to the fore of day-to-day clinical and research practice

This article discusses the major developments that have taken place in the PD genetics field, and provides an understanding of why and how genetics is increasingly being integrated into day-to-day clinical and research practice.

05.03.2025 Parkinson’s Disease
description Article
Substance Use Disorders and Behavioral Addictions with Special Consideration of Psychiatric Comorbidity

Individuals with addictive disorders frequently have medical and (underlying) psychiatric comorbid conditions and high disease burden

26.02.2025 Substance Use Disorders
image Image There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden (e.g., impaired movement, sleep disorders, pain, cognitive impairment, etc.).
Perceived caregiver burden as Parkinson’s disease advances

There are many aspects of Parkinson’s disease (PD) that can intensify the caregiver burden

22.02.2025 Parkinson’s Disease